Why the study?
Does the miR-34a-5p/Sirt1/p66shc pathway mediate anthracycline-induced cardiotoxicity in cardiomyocytes, animal models, and patients?
Does the miR-34a-5p/Sirt1/p66shc pathway mediate anthracycline-induced cardiotoxicity in cardiomyocytes, animal models, and patients?
The miR-34a-5p/Sirt1/p66shc pathway is a key mechanistic driver of anthracycline-induced cardiotoxicity, offering a potential therapeutic target for cardioprotection.
Answers are grounded in this paper and cite their sources.
Identifies a novel mechanistic target for anthracycline-induced cardiotoxicity; leaves.
The molecular mechanisms underlying anthracyclines-induced cardiotoxicity have not been well elucidated. MiRNAs were revealed dysregulated in the myocardium and plasma of rats received Dox treatment. MicroRNA-34a-5p (miR-34a-5p) was verified increased in the myocardium and plasma of Dox-treated rats, but was reversed in rats received Dox plus DEX treatments. Human miR-34a-5p was also observed increased in the plasma of patients with diffuse large B-cell lymphoma after 9- and 16-week epirubicin therapy. Up-regulation of miR-34a-5p was observed in Dox-induced rat cardiomyocyte H9c2 cells. MiR-34a-5p could augment Bax expression, but inhibited Bcl-2 expression, along with the increases of the activated caspase-3 and mitochondrial potentials in H9C2 cells. MiR-34a-5p was verified to modulate Sirt1 expression post-transcriptionally. In parallel to Sirt1 siRNA, miR-34a-5p could enhance p66shc expression, accompanied by increases of Bax and the activated caspase-3 and a decrease of Bcl-2 in H9c2 cells. Moreover, enforced expression of Sirt1 alleviated Dox-induced apoptosis of H9c2 cells, with suppressing levels of p66shc, Bax, the activated caspase-3 and miR-34a-5p, and enhancing Bcl-2 expression. Therefore, miR-34a-5p enhances cardiomyocyte apoptosis by targeting Sirt1, activation of miR-34a-5p/Sirt1/p66shc pathway contributes to Dox-induced cardiotoxicity, and blockage of this pathway represents a potential cardioprotective effect against anthracyclines.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: